Peptide Therapy With Dr. Kent Holtorf, MD
In this episode, you will learn about the use of peptide therapy in Lyme disease and related complex, chronic illnesses.
About My Guest: My guest for this episode is Dr. Kent Holtorf. Kent Holtorf, MD is the medical director of the Holtorf Medical Group. He is founder and director of the non-profit National Academy of Hypothyroidism (NAH), which is dedicated to dissemination of new information to doctors and patients on the diagnosis and treatment of hypothyroidism. He has personally trained numerous physicians across the country in the use of bioidentical hormones, hypothyroidism, complex endocrine dysfunction, and innovative treatments of Chronic Fatigue Syndrome, Fibromyalgia, and chronic infectious diseases, including Lyme disease. He is a fellowship lecturer for the American Board of Anti-aging Medicine, the Endocrinology Expert for AOL Health, and is a guest editor and peer-reviewer for a number of medical journals. Dr. Holtorf has published a number of peer-reviewed endocrine reviews, including on the safety and efficacy of bioidentical hormones, inaccuracies of standard thyroid testing, testosterone replacement for men and women, the diagnosis and treatment of growth hormone deficiency, and on the diagnosis and treatment of adrenal dysfunction in Chronic Fatigue Syndrome and Fibromyalgia. He has helped to demonstrate that much of the long-held dogma in endocrinology is inaccurate. He is a contributing author to Denis Wilson’s Evidenced-Based Approach to Restoring Thyroid Health. He has been a featured guest on CNBC, ABC News, CNN, EXTRA TV, Discovery Health, The Learning Channel, The Today Show, Dr. Dean Edell, Glenn Beck, Nancy Grace, Sean Hannity, and more and quoted in numerous print media including the Wall Street Journal, Los Angeles Times, US New and World Report, San Francisco Chronicle, WebMD, Elle, Better Homes and Garden, US Weekly, Forbes, Cosmopolitan, and Self magazine among many others.
- What are peptides?
- How are peptides created?
- What conditions might peptides be helpful for?
- What are the key contributors to aging?
- How are thymosins used to modulate the immune system?
- How is Th1/Th2 dominance measured?
- What is the role of LL37 in treating chronic infections?
- What is the connection between hypercoagulation and mast cell activation?
- How might BPC-157 be helpful in chronic illness?
- What is the role of Epithalon in anti-aging and regenerative strategies?
- How might peptides be helpful in conditions such as autism, Parkinson’s, and ALS?
- How well-tolerated are peptides by sensitive patient populations?
Connect With My Guest: http://holtorfmed.com
For more: https://examine.com/supplements/bpc-157/ (Go here for entire article)
BPC-157 is a peptide chain consisting of 15 amino acids. It is considered synthetic because this particular sequence does not exist in nature. It is derived from a protective protein found in the stomach.
Researchers have conducted numerous rodent studies on BPC-157 that show it has protective effects extending beyond the stomach and intestinal tract. BPC-157 has been shown to benefit ulcers in the stomach, intestinal damage such as fistulas and inflammatory disorders, bone and joint healing and growth rates, and organ damage. It also has some influences on the brain. Researchers have observed marked protective effects when BPC-157 is administered to rats alongside a research toxin or damaging surgical procedure.
More research is needed to clarify whether BPC-157 has multiple mechanisms of action, but current research suggests BPC-157 influences several growth factors usually involved in angiogenesis (the production of blood vessels) and other factors involved in regeneration following damage.
BPC-157 shows promise, but human studies are needed to demonstrate that these benefits extend beyond research animals.
The majority of studies on BPC-157 are done on rats given injections of the supplement. While BPC-157 is a stable peptide, peptides are a group of compounds that are normally poorly absorbed after oral supplementation, so researchers use injections in rodent studies instead. Furthermore, there is no human evidence for BPC-157 and the majority of the research has been conducted by a single research group. Due to its synthetic nature, there may be legal issues associated with the sale of this supplement in certain regions and it may be banned by some sport organizations.
BPC-157 appears to have protective effects on brain tissue when administered to rats (either in drinking water or injections) alongside the toxin cuprizone by reducing the amount of damaged cells in numerous brain regions, including the hippocampus. Cuprizone is a toxin used to mimic the damages seen in multiple sclerosis and potentially schizophrenia.
5.1. Collagen and Joints
Researchers have observed benefits when putting BPC-157 on a sponge during surgery, where it appeared to improve the rate of collagen reformation, initially outperforming platelet-growth factor after four days but eventually being equipotent after eight days. Benefits have been seen in rats given intraperitoneal injections after an Achilles heel injury, where the rate of injury healing was visually confirmed with smaller cut size and depth.
Most BPC-157 studies on intestinal damage use rats that undergo surgical-induced damage for experimental purposes. BPC-157 appears to have very potent protective effects in rats by mitigating damage to the tissue and structural abnormalities caused by the damage.
It is possible, based on limited evidence, that BPC-157 may be orally active in the alimentary canal (the pathway between the mouth and anus).
One study in rats using the toxin MPTP (which induces damage similar to what is seen in Parkinson’s Disease in rodents), administration of BPC-157 intraperitoneally appeared to mitigate some of the damage caused by MPTP.
In rodents given cuprizone (to induce damage similar to what is seen in multiple sclerosis) those given BPC-157 alongside the cuprizone (0.16 ng/mL or 0.16 μg/mL in drinking water over four days or 10 ng/kg or 10 μg/kg intragastrically on the final day) seemed to exhibit significantly less brain damage and clinical abnormalities from the cuprizone than did control rats not given BPC-157.
“BPC-157,” Examine.com, published on 14 April 2017, last updated on 14 June 2018,https://examine.com/supplements/BPC-157/